Extranodal extension
OtherExtranodal extension presence or absence on radiology and pathology assessment
NCT Number: NCT05936502
Extranodal extension (ENE) refers to the spread of head and neck squamous cell carcinoma (HNSCC) outside the lymph nodes. It is a well-known factor that indicates a poorer prognosis and outcome for patients who have undergone surgical removal of the cancer. In such cases, it is recommended to combine chemotherapy with radiation therapy after surgery.
As the number of cases of HNSCC related to the human papillomavirus (HPV) is increasing, treatment approaches have shifted towards using radiation therapy as the primary treatment method instead of surgery. This raises an important question about the significance of ENE observed through imaging tests (referred to as iENE) and its impact on the prognosis. Unfortunately, this question remains unanswered.
The objective of this project is to conduct a comprehensive study across multiple medical institutions. The investigators will gather data including scan results, histopathology reports, and data from patient charts from individuals who have been treated for head and neck cancer. The aim is to analyze and correlate the findings between the pathological evidence of ENE and the imaging results, while also assessing the prognostic value of iENE. Additionally, the investigators will explore the influence of HPV status on these factors.
By collecting and analyzing this data, the investigators hope to establish standardized criteria that can assist radiologists in accurately identifying ENE through imaging tests. This research is essential for enhancing our understanding of HNSCC and improving the effectiveness of diagnostic procedures and treatment planning.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Royal Adelaide Hospital, Adelaide, Australia
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
The investigators will examine data from consecutive patients at each site treated between 1/1/1999 and 12/31/2020. Patients must fulfil all these criteria:
i. Been treated for oral cavity, oropharyngeal, carcinoma of unknown primary, laryngeal, or hypopharyngeal squamous cell carcinoma and be over the age of 18.
ii. The participants must have been treated with curative intent via surgery, radiotherapy, or chemoradiotherapy or a combination within the study inclusion period.
iii. The participants must have had CT or/and MRI scans of the neck, performed within 12 weeks before the start of treatment.
iv. Results for the presence or absence of extranodal extension on CT or/and MRI scans, or ability to report them within the deadline period.
v. For surgically-treated patients: Results for the presence or absence of both extranodal extension on histopathology and on radiology, or ability to report them within the deadline period.
vi. Must have had at least two years of follow-up, or death. vii. Data on staging must be available at least in TNM 7th edition or later editions.
Exclusion criteria
i. Patients who were diagnosed with distant metastasis at presentation. ii. Patients treated palliatively at first presentation iii. Patients presenting with recurrent disease who don't meet all the eligibility criteria above
-
Extranodal extension presence or absence on radiology and pathology assessment
Time frame: 31 December 2023
Endpoints: Accuracy of a radiologic "call" of iENE (with pENE being the gold standard comparator) by radiologists not trained for any standardized diagnostic classification systems for iENE.
Time frame: 31 December 2023
Endpoints: Overall survival rates based on presence of iENE and pENE
Time frame: 31 December 2023
Endpoints: Recurrence rates based on presence of iENE and pENE
Time frame: 31 December 2023
Endpoints: Overall survival rates based on presence of various degrees of iENE and pENE
Time frame: 31 December 2023
Endpoints: Recurrence rates based on presence of various degrees of iENE and pENE
Time frame: 31 December 2023
Endpoints: Diagnostic accuracy of various radiographic features of iENE with pENE.
Time frame: 31 December 2023
Endpoints: Diagnostic accuracy of published standardized classification systems with pENE
Time frame: 31 December 2023
Endpoints: Interobserver variability measured by Cohen's kappa
Head and Neck Cancer International Group
Other
Ascertaining the Radiologic Prognostic Importance of Extranodal Extension on Imaging (iENE) in Head and Neck Cancer Part of the Evaluation Prognostic and Predictive Indicators in Head and Neck Cancer (EPIC) Programme, Run Under the Auspices of the Head and Neck Inter Group (HNCIG, Www.Hncig.Org)
Acronym: EPIC-iENE DATA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06307093
Carcinoma, Carcinoma, Squamous Cell
Istra, Moscow Oblast, Russia
View Trial DetailsNCT07435324
Carcinoma, Carcinoma, Squamous Cell
Arkhangelsk, Russia
View Trial DetailsNCT07435311
Carcinoma, Carcinoma, Squamous Cell
Barnaul, Russia
View Trial DetailsNCT07682285
Cancer-related Fatigue, Carcinoma
Taipei, Taiwan
View Trial Details